Epstein‐Barr virus miR‐BART2‐5p and miR‐BART11‐5p regulate cell proliferation, apoptosis, and migration by targeting RB and p21 in gastric carcinoma

Epstein‐Barr virus (EBV) was the first tumor virus discovered in humans and can cause various types of tumors. Molecular classification suggests that EBV‐associated gastric cancer (EBVaGC) is a unique subtype of gastric cancer.EBV was also the first virus found to encode its own microRNAs. However, the functions of many miRNAs remain unknown. This study investigated the roles and targets of miR‐BART2‐5p (BART2‐5p) and miR‐BART11‐5p (BART11‐5p) in EBVaGC. The expression of RB and p21 in EBVaGC and EBV negative GC (EBVnGC) cells was evaluated by western blotting. Expression of BART2‐5p and BART11‐5p in EBVaGC cells was evaluated by droplet digital PCR. The effects of BART2‐5p or BART11‐5p and their potential mechanisms were further investigated using cell counting kit‐8, colony formation assay, flow cytometry analysis, and transwell assay. BART2‐5p and BART11‐5p were abundantly expressed and RB and p21 were downregulated in EBVaGC cells. BART2‐5p regulates RB and p21 expression by directly targeting them. BART11‐5p regulates RB expression by directly targeting RB. Both BART2‐5p and BART11‐5p promoted proliferation and migration of gastric cancer cells, while inhibiting apoptosis and promoting S‐phase arrest of the cell cycle. Thus, BART2‐5p and BART11‐5p play important roles in promoting proliferation and migration, and inhibiting apoptosis in EBVaGC by targeting RB and p21, thus providing new potential therapeutic targets for EBVaGC.

[1]  Mingxiang Teng,et al.  The Epstein-Barr Virus Enhancer Interaction Landscapes in Virus-Associated Cancer Cell Lines , 2022, Journal of virology.

[2]  A. Vidal-Realpe,et al.  Clinical and pathologic characteristics of gastric adenocarcinoma associated with Epstein-Barr virus in a region with a high incidence of gastric cancer in Colombia. , 2022, Revista de gastroenterologia de Mexico.

[3]  Matthias Simon,et al.  Mechanisms of Cell Cycle Arrest and Apoptosis in Glioblastoma , 2022, Biomedicines.

[4]  Z. Zeng,et al.  EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1 , 2022, Nature communications.

[5]  Chao Cheng,et al.  Deep Learning Predicts EBV Status in Gastric Cancer Based on Spatial Patterns of Lymphocyte Infiltration , 2021, Cancers.

[6]  Zhentan Lu,et al.  A simple colorimetric method for viable bacteria detection based on cell counting Kit-8. , 2021, Analytical methods : advancing methods and applications.

[7]  Jasmine Chen,et al.  Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epithelium , 2021, Oncogene.

[8]  K. Kono,et al.  Landscape of EBV-positive gastric cancer , 2021, Gastric Cancer.

[9]  S. Yom,et al.  Nasopharyngeal Carcinoma and Its Association with Epstein-Barr Virus. , 2021, Hematology/oncology clinics of North America.

[10]  Lizhao Wu,et al.  The Role and Clinical Implications of the Retinoblastoma (RB)-E2F Pathway in Gastric Cancer , 2021, Frontiers in Oncology.

[11]  S. Soltani,et al.  A review on EBV encoded and EBV-induced host microRNAs expression profile in different lymphoma types , 2021, Molecular Biology Reports.

[12]  A. Corvalán,et al.  EBV miR-BARTs and human lncRNAs: Shifting the balance in competing endogenous RNA networks in EBV-associated gastric cancer. , 2021, Biochimica et biophysica acta. Molecular basis of disease.

[13]  Long Yu,et al.  Cyclin Y binds and activates CDK4 to promote the G1/S phase transition in hepatocellular carcinoma cells via Rb signaling. , 2020, Biochemical and biophysical research communications.

[14]  Jian-ning Chen,et al.  EBV-miR-BART10-3p and EBV-miR-BART22 promote metastasis of EBV-associated gastric carcinoma by activating the canonical Wnt signaling pathway , 2020, Cellular Oncology.

[15]  Shan Liao,et al.  Epstein-Barr virus-encoded miR-BART11 promotes tumor-associated macrophage-induced epithelial-mesenchymal transition via targeting FOXP1 in gastric cancer. , 2020, Virology.

[16]  S. Yun,et al.  Epstein–Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas , 2020, Gastric Cancer.

[17]  J. Yun,et al.  Epstein–Barr Virus miRNA BART2-5p Promotes Metastasis of Nasopharyngeal Carcinoma by Suppressing RND3 , 2020, Cancer Research.

[18]  Danxia Zhu,et al.  Circulating Epstein-Barr virus microRNA profile reveals novel biomarker for nasopharyngeal carcinoma diagnosis. , 2020, Cancer biomarkers : section A of Disease markers.

[19]  H. Gali-Muhtasib,et al.  The Role of the Cyclin Dependent Kinase Inhibitor p21cip1/waf1 in Targeting Cancer: Molecular Mechanisms and Novel Therapeutics , 2019, Cancers.

[20]  C. Münz Latency and lytic replication in Epstein–Barr virus-associated oncogenesis , 2019, Nature Reviews Microbiology.

[21]  Reactivating RB via CDK2 Inhibition Reduces Lung Cancer Aggressiveness. , 2019, Cancer Discovery.

[22]  Jianhong Lu,et al.  Epstein–Barr virus miR-BART3-3p promotes tumorigenesis by regulating the senescence pathway in gastric cancer , 2019, The Journal of Biological Chemistry.

[23]  L. Ellis,et al.  The Role of RB in Prostate Cancer Progression. , 2019, Advances in experimental medicine and biology.

[24]  D. Kwong,et al.  Evaluation of circulating EBV microRNA BART2‐5p in facilitating early detection and screening of nasopharyngeal carcinoma , 2018, International journal of cancer.

[25]  M. Takahara,et al.  Circulating Epstein‐Barr virus–encoded micro‐RNAs as potential biomarkers for nasal natural killer/T‐cell lymphoma , 2017, Hematological oncology.

[26]  Kwok Wai Lo,et al.  Epstein–Barr virus infection and nasopharyngeal carcinoma , 2017, Philosophical Transactions of the Royal Society B: Biological Sciences.

[27]  J. Grenert,et al.  Concomitant Epstein-Barr Virus-associated smooth muscle tumor and granulomatous inflammation of the liver. , 2017, Pathology, research and practice.

[28]  A. Rickinson,et al.  Epstein–Barr virus-associated lymphomas , 2017, Philosophical Transactions of the Royal Society B: Biological Sciences.

[29]  H. Sousa,et al.  Epstein-Barr virus gene expression and latency pattern in gastric carcinomas: a systematic review. , 2017, Future oncology.

[30]  Lisa A Antonucci,et al.  Dephosphorylation of the Retinoblastoma protein (Rb) inhibits cancer cell EMT via Zeb , 2016, Cancer biology & therapy.

[31]  Ansar Karimian,et al.  Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. , 2016, DNA repair.

[32]  Rashmi Kanagal-Shamanna,et al.  Digital PCR: Principles and Applications. , 2016, Methods in molecular biology.

[33]  M. Fukayama,et al.  Update on Epstein-Barr virus and gastric cancer (review). , 2015, International journal of oncology.

[34]  M. Rederstorff,et al.  Dual luciferase gene reporter assays to study miRNA function. , 2015, Methods in molecular biology.

[35]  F. Marincola,et al.  EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN , 2014, Oncogene.

[36]  Jukka Westermarck,et al.  ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays , 2014, PloS one.

[37]  P. Meltzer,et al.  A p21-ZEB1 Complex Inhibits Epithelial-Mesenchymal Transition through the MicroRNA 183-96-182 Cluster , 2013, Molecular and Cellular Biology.

[38]  Pauline E. Chugh,et al.  Expression Profile of MicroRNAs in Epstein-Barr Virus-Infected AGS Gastric Carcinoma Cells , 2013, Journal of Virology.

[39]  S. Kojima,et al.  Plasma viral microRNA profiles reveal potential biomarkers for chronic active Epstein-Barr virus infection. , 2013, The Journal of infectious diseases.

[40]  Tomokazu Yoshizaki,et al.  Pathogenic role of Epstein-Barr virus latent membrane protein-1 in the development of nasopharyngeal carcinoma. , 2013, Cancer letters.

[41]  M. Gandhi,et al.  The Epstein-Barr virus microRNA BART11-5p targets the early B-cell transcription factor EBF1. , 2013, American journal of blood research.

[42]  Frederick A. Dick,et al.  Molecular mechanisms underlying RB protein function , 2013, Nature Reviews Molecular Cell Biology.

[43]  A. Giordano,et al.  Emerging roles of RB family: New defense mechanisms against tumor progression , 2013, Journal of cellular physiology.

[44]  W. El-Deiry,et al.  p21WAF1 and tumourigenesis: 20 years after , 2013, Current opinion in oncology.

[45]  Chengquan Zhao,et al.  Methylation and Expression of Retinoblastoma and Transforming Growth Factor-β1 Genes in Epstein-Barr Virus-Associated and -Negative Gastric Carcinomas , 2012, Gastroenterology research and practice.

[46]  J. Marshall Transwell(®) invasion assays. , 2011, Methods in molecular biology.

[47]  K. Takada,et al.  Role of EBERs in the pathogenesis of EBV infection. , 2010, Advances in cancer research.

[48]  Raymond Wai-Ming Lung,et al.  Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. , 2009, Neoplasia.

[49]  A. Giordano,et al.  RB and cell cycle progression , 2006, Oncogene.

[50]  E. Harlow,et al.  The retinoblastoma tumour suppressor in development and cancer , 2002, Nature Reviews Cancer.

[51]  P. Dennis,et al.  The LMP2A signalosome--a therapeutic target for Epstein-Barr virus latency and associated disease. , 2002, Frontiers in bioscience : a journal and virtual library.

[52]  Z. Darżynkiewicz,et al.  Flow cytometry in analysis of cell cycle and apoptosis. , 2001, Seminars in hematology.

[53]  M. Datto,et al.  RB regulates transcription of the p21/WAF1/CIP1 gene , 2001, Oncogene.

[54]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[55]  U. Nater,et al.  Epstein-Barr virus. , 1991, The Journal of family practice.